Abstract
There is an increasing amount of evidence showing the importance of intermediate aggregation species of amyloid β (Aβ) in the pathogenic cascade of Alzheimers disease (AD). Different Aβ assembly forms may mediate diverse toxic effects at different stages of the disease. Mouse models for AD suggest that intraneuronal accumulation of Aβ oligomers might be involved in AD pathogenesis at a very early stage of the disease. The detrimental effect of oligomeric Aβ on synaptic efficacy is suggested to be an early event in the pathogenic cascade. Also early neuronal responses as activation of the unfolded protein response are processes likely to be associated with the increased occurrence of oligomeric or low fibrillar Aβ in AD pathology. In later stages of AD pathology, the fibrillarity of Aβ increases, concomitantly with a neuroinflammatory response, followed by tau related neurofibrillary changes in end stage pathology. We will review recent findings in in vitro cell models, in vivo mouse models, and post mortem AD brain tissue in view of the effects of different Aβ peptide species on neurodegeneration during AD pathogenesis. Insight into the role of different Aβ species during AD pathogenesis is essential for the development of disease modifying drugs and therapeutical strategies.
Keywords: Alzheimer's disease, amyloid β, aggregation, ER stress, neuroinflammation, neurotoxicity, pathological cascade, unfolded protein response
Current Medicinal Chemistry
Title: Always Around, Never the Same: Pathways of Amyloid Beta Induced Neurodegeneration Throughout the Pathogenic Cascade of Alzheimers Disease
Volume: 13 Issue: 22
Author(s): J. J. M.Hoozemans, S. M. Chafekar, F. Baas, P. Eikelenboom and W. Scheper
Affiliation:
Keywords: Alzheimer's disease, amyloid β, aggregation, ER stress, neuroinflammation, neurotoxicity, pathological cascade, unfolded protein response
Abstract: There is an increasing amount of evidence showing the importance of intermediate aggregation species of amyloid β (Aβ) in the pathogenic cascade of Alzheimers disease (AD). Different Aβ assembly forms may mediate diverse toxic effects at different stages of the disease. Mouse models for AD suggest that intraneuronal accumulation of Aβ oligomers might be involved in AD pathogenesis at a very early stage of the disease. The detrimental effect of oligomeric Aβ on synaptic efficacy is suggested to be an early event in the pathogenic cascade. Also early neuronal responses as activation of the unfolded protein response are processes likely to be associated with the increased occurrence of oligomeric or low fibrillar Aβ in AD pathology. In later stages of AD pathology, the fibrillarity of Aβ increases, concomitantly with a neuroinflammatory response, followed by tau related neurofibrillary changes in end stage pathology. We will review recent findings in in vitro cell models, in vivo mouse models, and post mortem AD brain tissue in view of the effects of different Aβ peptide species on neurodegeneration during AD pathogenesis. Insight into the role of different Aβ species during AD pathogenesis is essential for the development of disease modifying drugs and therapeutical strategies.
Export Options
About this article
Cite this article as:
M.Hoozemans J. J., Chafekar M. S., Baas F., Eikelenboom P. and Scheper W., Always Around, Never the Same: Pathways of Amyloid Beta Induced Neurodegeneration Throughout the Pathogenic Cascade of Alzheimers Disease, Current Medicinal Chemistry 2006; 13 (22) . https://dx.doi.org/10.2174/092986706778201585
DOI https://dx.doi.org/10.2174/092986706778201585 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
Current advances in inherited cardiomyopathy
Describe in detail all novel advances in multimodality imaging related to inherited cardiomyopathy diagnosis and prognosis. Shed light to deeper phenotypic characterization. Acknowledge recent advances in genetics, genomics and precision medicineread more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Glycogen Synthase Kinase 3 as an Anticancer Drug Target: Novel Experimental Findings and Trends in the Design of Inhibitors
Current Pharmaceutical Design Current Trends in Drug Delivery System of Curcumin and its Therapeutic Applications
Mini-Reviews in Medicinal Chemistry Cognitive - Behavioral Therapy in Central Sensitivity Syndromes
Current Rheumatology Reviews The Novel Antipsychotic Cariprazine (RGH-188): State-of-the-Art in the Treatment of Psychiatric Disorders
Current Pharmaceutical Design Dynamic Crosstalk between GlcNAcylation and Phosphorylation: Roles in Signaling, Transcription and Human Disease
Current Signal Transduction Therapy Mild Cognitive Impairment (MCI) - The Novel Trend of Targeting Alzheimers Disease in Its Early Stages - Methodological Considerations
Current Alzheimer Research Validation of Texas Christian University Psychosocial Functioning and Motivation Scales in Iranian Persons Who Use Drugs
Current Drug Research Reviews Platelets as Potential Link Between Diabetes and Alzheimer's Disease
Current Alzheimer Research The Role of the Metabolism of Anticancer Drugs in Their Induced-Cardiotoxicity
Current Drug Metabolism Restoration of the Immune Balance by Autologous Bone Marrow Transplantation in Juvenile Idiopathic Arthritis
Current Stem Cell Research & Therapy Commentary: Fatal French Clinical Trial: What Can We Learn from What Went Wrong?
CNS & Neurological Disorders - Drug Targets Modulation of the FGF14:FGF14 Homodimer Interaction Through Short Peptide Fragments
CNS & Neurological Disorders - Drug Targets Atherosclerotic Plaque Stabilization - Potential Role for Immunomodulatory Therapy
Vascular Disease Prevention (Discontinued) Opioid Peptides and Their Glycoconjugates: Structure-Activity Relationships
Current Medicinal Chemistry - Central Nervous System Agents Engineered Polymer Nanoplatforms for Targeted Tumor Cells and Controlled Release Cargos to Enhance Cancer Treatment
Current Medicinal Chemistry Recent Development of Vegetal Tannins in Corrosion Protection of Iron and Steel
Recent Patents on Materials Science Pathological Gambling: Neuropsychopharmacology and Treatment
Current Psychopharmacology YKL-40 as a Potential Biomarker and a Possible Target in Therapeutic Strategies of Alzheimer’s Disease
Current Neuropharmacology Review of Synthesis, Biological Assay and QSAR Studies of β-Secretase Inhibitors
Current Computer-Aided Drug Design Targeting the Nrf2-Heme Oxygenase-1 Axis after Intracerebral Hemorrhage
Current Pharmaceutical Design